Smith & Nephew's VersaBond
This article was originally published in The Gray Sheet
Executive Summary
Medium viscosity bone cement for use in shoulder, hip and knee replacement procedures will be available for sale in late February following 510(k) clearance in December. Manufactured in Germany by Coripharm Medizinprodukte CmbH & Co., the product is the first bone cement cleared via 510(k) since downclassification of such devices from Class III to Class II
You may also be interested in...
Parkinson’s Results Further Sweeten AbbVie’s Acquisition of Cerevel
Cerevel, which AbbVie is spending $8.7bn to acquire, unveiled topline results from the TEMPO-3 study of tavapadon, which an analyst said represents potentially a $1bn opportunity.
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.